Moderna GAAP EPS of $8.58 beats by $3.37, revenue of $6.1B beats by $1.67B
Moderna press release (NASDAQ:MRNA): Q1 GAAP EPS of $8.58  beats by $3.37.
Revenue of $6.1B (+214.4% Y/Y)  beats by $1.67B.
The increase in 2022 was primarily due to increased product sales. Product sales for the first quarter of 2022 were $5.9 billion from sales of the Company's COVID vaccine, compared to $1.7 billion in the first quarter of 2021.

Shares +2.7% PM.
Moderna reiterates its 2022 signed advance purchase agreements of approximately $21 billion
FY22 Outlook
Research & Development (R&D) and Selling, General & Administrative (SG&A) Expenses : Full year expenses expected to be approximately $4 billion.
Tax Rate: The Company expects an effective tax rate for the full year in the mid-teen percentage range.
Capital Expenditures: Expect capital investments for 2022 in the range of $0.6-$0.8 billion.
Cost of Sales: Cost of sales as percentage of product sales are expected to be in the low-to-mid 20s percentage range.